- Condition: Factory New
-
Learn more:
- MFR: Smith & Nephew Ships from MFI Medical
- MPN: 66801275
- Phone: (800) 876-1261
Frequently asked questions
Does this canister enhance clinical outcomes?
Yes, this RENASYS TCH 300 CANISTER is specifically designed to assist clinicians in improving patient clinical outcomes by serving as a versatile system accessory for advanced wound device portfolios.
Is this canister compatible with other devices?
Absolutely! It is designed to complement Smith & Nephew’s advanced wound device portfolio, offering crucial flexibility for diverse wound care needs in clinical environments.
What is the condition of this product?
This product is supplied in Factory New condition, ensuring reliability for critical medical applications right out of the box.
What is the Manufacturer Part Number (MPN)?
The Manufacturer Part Number (MPN) for this RENASYS TCH 300 CANISTER is 66801275.
What is the typical lead time for this item?
The typical lead time for this product is 2-3 weeks, as it ships directly from the manufacturer.
How much does the canister weigh?
The Smith & Nephew RENASYS TCH 300 Canister is very lightweight, with a default variant weight of only 0.01 pounds.
Where does this product ship from?
This product Ships from Manufacturer, ensuring you receive a Factory New item directly.
Please note that because the item ships from the manufacturer, the standard lead time for delivery is 2-3 Weeks (approximately 17 days).
Is this product suitable for specific medical uses?
Yes, it is ideal for use in clinical settings that require negative pressure wound therapy systems and is intended to be paired with Smith & Nephew’s advanced wound device portfolio.
Is this canister a critical accessory?
Yes, it is an essential accessory for maintaining negative pressure therapy cycles, offering critical flexibility for specialized wound care.
Is this a versatile system accessory?
Yes, the RENASYS TCH 300 CANISTER NOSLD is designed as a versatile system accessory. Its primary function is to support clinicians by enhancing patient clinical outcomes within advanced wound device portfolios.